News
DONATE

Support Line: 833-275-4222

Walk to End Bladder Cancer

Back to Clinical Trials

Brief Title: Home-Based Physical Activity Program With Digital App Versus Health Education Group for Improving Physical Activity Among Patients With Non-muscle Invasive Bladder Cancer, The EMPOWER Trial

Back to Clinical Trials

The EMPOWER Trial: Evaluating a Home-Based Physical Activity Program (PAP) With the ExerciseRx™ Digital Platform vs. Health Education Group (HEG) in People With Non-Muscle Invasive Bladder Cancer

INTRODUCTION

  • Org Study ID: RG1125987
  • Secondary ID: N/A
  • NCT ID: NCT07302230
  • Sponsor: University of Washington

BRIEF SUMMARY

This clinical trial compares how well a home-based personalized physical activity program (PAP) that is delivered by a digital application (app) (the ExerciseRx app) works compared to health education in improving physical activity for patients with bladder cancer that has not reached the muscle wall of the bladder (non-muscle invasive). For people who are not physically active, previous studies have shown that increasing step counts can reduce incidence of death, reduce frailty, and reduce healthcare costs. The ExerciseRx app tracks adherence to home exercise, adapts step count goals based on the patient's progress, and provides encouraging feedback and motivation from the healthcare team. Additional features include activity summaries, progress towards current goal, nudges, helpful facts about the benefits of activity, and ideas for how to incorporate daily movement. A home-based PAP using the ExerciseRx app may work better in increasing physical activity among patients with non-muscle invasive bladder cancer compared to a health education only group.

DETAILED DESCRIPTION

OUTLINE: Patients are randomized to 1 of 2 groups.

GROUP I (Health Education Group, HEG): Patients receive recommendations from their physicians and an educational pamphlet describing physical activity goals in line with National Comprehensive Cancer Network (NCCN) Survivorship for Healthy Living Guidelines. They receive a FitBit® to wear continuously throughout the study, with the ExerciseRx app locked to the baseline home screen.

GROUP II (PAP INTERVENTION): Patients complete home exercise sessions given via the ExerciseRx app over 20-30 minutes 4 times per week for 12 weeks and receive personalized daily step count goals that gradually increase over the study period. Patients also receive a FitBit® to wear continuously throughout the study, are given access to features of the ExerciseRx app (step count goals, home exercise videos), and receive an educational pamphlet as in Group I.

After completion of the study intervention, patients are followed up at 4 weeks.

  • Overall Status
    Recruiting
  • Start Date
    March 11, 2026
  • Phase
    Not Applicable
  • Study Type
    Interventional

PRIMARY OUTCOMES

Primary Outcome 1 - Measure: Change in mean daily step count

Primary Outcome 1 - Timeframe: Baseline (1 week prior to trial initiation) and timepoint 2 (12 weeks)

Primary Outcome 2 - Measure: Qualitative experience

Primary Outcome 2 - Timeframe: Week 16

CONDITION

  • Localized Non-Muscle Invasive Bladder Urothelial Carcinoma
  • Stage 0a Bladder Cancer AJCC v8
  • Stage 0is Bladder Cancer AJCC v8
  • Stage I Bladder Cancer AJCC v8

ELIGIBILITY

Inclusion Criteria:
* Adults (age >= 18 years)

- * Prior diagnosis of non-muscle invasive bladder cancer (NMIBC), currently on surveillance or receiving maintenance intravesical therapy (including intravesical chemotherapy, immunotherapy)

- * Classified as insufficiently active on the Physical Activity as a Vital Sign (PAVS) assessment

- * Has an Android or Apple Smartphone/Tablet

- * Ambulatory

- * English-speaking

- * Willing and able to participate in study activities and sign the informed consent form
Exclusion Criteria:
* Severe cognitive or memory impairment/dementia precluding ability to follow instructions or participate in survey assessments

- * Inability to read or understand English

- * Lack of access or lack of sufficient facility to use an Android or iOS smart device with the minimum criteria to run the ExerciseRx app

- * Not receiving treatment at University of Washington (UW)

- * Orthopedic, neurologic, or other problems that prevent safe ambulation and protocol adherence. Information on prior falls and other recent orthopedic or neurologic problems will be used to make judgment about protocol eligibility

- * Inability/Unwillingness to participate in a personalized exercise program

- * Current diagnosis with muscle-invasive or metastatic bladder cancer

- * Uncontrolled or concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

- * Lack of access or lack of sufficient facility to use an Android or iOS smart device with the minimum criteria for using the ExerciseRx app

- * Participation in a clinical trial that does not permit enrollment in the EMPOWER trial

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

OFFICIAL INFORMATION

Name: Sarah Psutka, MD, MSc

Role: Principal Investigator

Affiliation: Fred Hutch/University of Washington Cancer Consortium

Overall Contact

Name: Sarah Psutka, MD, MSc

Phone: 206-210-4040

Email: [email protected]

LOCATION

Facility Status Contact
Facility: Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington 98109
United States 		Status: Recruiting Contact: Contact
Sarah Psutka, MD, MSc
206-210-4040
[email protected]

Principal Investigator
Sarah Psutka, MD, MSc

Related Stories